116 related articles for article (PubMed ID: 15271398)
1. Monitoring of minimal residual disease in chronic myeloid leukemia.
Faderl S; Hochhaus A; Hughes T
Hematol Oncol Clin North Am; 2004 Jun; 18(3):657-70, ix-x. PubMed ID: 15271398
[TBL] [Abstract][Full Text] [Related]
2. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
3. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
[TBL] [Abstract][Full Text] [Related]
4. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
[TBL] [Abstract][Full Text] [Related]
5. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. The European Investigators on Chronic Myeloid Leukemia Group.
Lion T
Bone Marrow Transplant; 1994 Oct; 14(4):505-9. PubMed ID: 7532063
[TBL] [Abstract][Full Text] [Related]
6. Standardisation of molecular monitoring for chronic myeloid leukaemia.
Cross NC
Best Pract Res Clin Haematol; 2009 Sep; 22(3):355-65. PubMed ID: 19959086
[TBL] [Abstract][Full Text] [Related]
7. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
[TBL] [Abstract][Full Text] [Related]
8. The detection and significance of minimal residual disease in chronic myeloid leukemia.
Radich JP
Medicina (B Aires); 2000; 60 Suppl 2():66-70. PubMed ID: 11188935
[TBL] [Abstract][Full Text] [Related]
9. Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance.
Paschka P; Merx K; Hochhaus A
Acta Haematol; 2004; 112(1-2):85-92. PubMed ID: 15179008
[TBL] [Abstract][Full Text] [Related]
10. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
11. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I; Saglio G; Rosti G; Testoni N; Pane F; Amabile M; Poerio A; Soverini S; Bassi S; Cilloni D; Bassan R; Breccia M; Lauria F; Izzo B; Merante S; Frassoni F; Paolini S; Montefusco E; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 May; 12(10):3037-42. PubMed ID: 16707599
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of minimal residual disease using WT1 assay for patients with chronic myeloid leukemia who undergo allogeneic stem cell transplantation.
Tamaki H; Ogawa H
Bone Marrow Transplant; 2004 Oct; 34(7):653-4. PubMed ID: 15258561
[No Abstract] [Full Text] [Related]
13. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
[TBL] [Abstract][Full Text] [Related]
14. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
[TBL] [Abstract][Full Text] [Related]
15. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic efficacy for measurement of real-time quantitative PCR-based major bcr/abl mRNA in patients with Philadelphia chromosome-positive leukemia].
Takahata M; Hashino S; Fujisawa F; Kondo T; Ota S; Kobayashi S; Tanaka J; Imamura M; Asaka M
Rinsho Ketsueki; 2004 Dec; 45(12):1241-6. PubMed ID: 15678915
[TBL] [Abstract][Full Text] [Related]
17. [Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR].
Moravcová J; Brdicka R
Cas Lek Cesk; 2005; 144(1):32-7. PubMed ID: 15789779
[TBL] [Abstract][Full Text] [Related]
18. Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors.
Sahay T; Schiffer CA
Curr Opin Hematol; 2008 Mar; 15(2):134-9. PubMed ID: 18300760
[TBL] [Abstract][Full Text] [Related]
19. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
[TBL] [Abstract][Full Text] [Related]
20. Detection and monitoring of minimal residual disease by quantitative real-time PCR.
Schüler F; Dölken G
Clin Chim Acta; 2006 Jan; 363(1-2):147-56. PubMed ID: 16154122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
